Mechanism of Action of Levetiracetam (Keppra)

Introduction

Levetiracetam (brand name: Keppra) is a broad-spectrum antiepileptic drug used in the management of partial seizures, myoclonic seizures, and generalized tonic-clonic seizures. It is known for its unique mechanism of action, favorable safety profile, and minimal drug interactions, making it widely used in both adults and pediatric patients.

Mechanism of Action (Step-wise)

1. Binding to Synaptic Vesicle Protein 2A (SV2A)
   Levetiracetam selectively binds to SV2A, a protein located on presynaptic vesicles in neurons.
2. Modulation of Neurotransmitter Release
   Binding to SV2A regulates vesicle exocytosis, reducing excessive neurotransmitter release.
3. Inhibition of Excitatory Neurotransmission
   It decreases the release of excitatory neurotransmitters such as glutamate.
4. Stabilization of Neuronal Activity
   By limiting excessive synaptic transmission, it stabilizes neuronal firing and prevents seizure propagation.
5. Reduction of Hypersynchronization
   It inhibits abnormal neuronal synchronization that is characteristic of epileptic activity.
6. Minimal Effect on Normal Neurotransmission
   Levetiracetam selectively targets pathological activity with minimal effect on normal neuronal signaling.

Pharmacokinetics

• Administration: Oral and intravenous
• Absorption: Rapid and almost complete
• Bioavailability: ~100%
• Protein Binding: Minimal
• Metabolism: Minimal hepatic metabolism
• Half-life: ~6–8 hours
• Excretion: Renal (primarily unchanged)

Clinical Uses

• Partial (focal) seizures
• Generalized tonic-clonic seizures
• Myoclonic seizures (especially in juvenile myoclonic epilepsy)
• Status epilepticus (off-label use)

Adverse Effects

• Somnolence
• Dizziness
• Fatigue
• Behavioral changes (irritability, aggression)
• Headache

Comparative Analysis

Levetiracetam is preferred due to its unique SV2A-mediated mechanism, minimal drug interactions, and lack of significant hepatic metabolism. Compared to phenytoin and valproate, it has a better safety and tolerability profile.

MCQs

1. Levetiracetam binds to which protein?
   a) GABA receptor
   b) Sodium channel
   c) SV2A
   d) NMDA receptor
   Answer: c) SV2A
2. Main effect of levetiracetam:
   a) Increase dopamine
   b) Reduce glutamate release
   c) Block calcium channels
   d) Increase serotonin
   Answer: b) Reduce glutamate release
3. Levetiracetam is used in:
   a) Hypertension
   b) Epilepsy
   c) Diabetes
   d) Asthma
   Answer: b) Epilepsy
4. Bioavailability of levetiracetam:
   a) 50%
   b) 70%
   c) 100%
   d) 30%
   Answer: c) 100%
5. Major route of excretion:
   a) Hepatic
   b) Renal
   c) Pulmonary
   d) Biliary
   Answer: b) Renal
6. Levetiracetam has:
   a) High protein binding
   b) Minimal protein binding
   c) No absorption
   d) High metabolism
   Answer: b) Minimal protein binding
7. Compared to phenytoin, levetiracetam:
   a) Has more interactions
   b) Has fewer interactions
   c) Is less effective
   d) Is more toxic
   Answer: b) Has fewer interactions
8. Behavioral side effects include:
   a) Hypotension
   b) Aggression
   c) Bradycardia
   d) Constipation
   Answer: b) Aggression
9. Mechanism involves:
   a) Sodium channel block
   b) SV2A modulation
   c) Calcium channel activation
   d) GABA breakdown
   Answer: b) SV2A modulation
10. Levetiracetam is suitable for:
    a) Only focal seizures
    b) Only generalized seizures
    c) Broad-spectrum seizure control
    d) Pain management
    Answer: c) Broad-spectrum seizure control

FAQs

1. What is the mechanism of action of levetiracetam?
   It binds to SV2A and modulates neurotransmitter release to prevent seizures.
2. Why is levetiracetam widely used?
   Due to its safety, minimal interactions, and broad-spectrum activity.
3. Does levetiracetam affect liver enzymes?
   No, it has minimal hepatic metabolism.
4. Can levetiracetam cause behavioral changes?
   Yes, irritability and aggression may occur.
5. Is levetiracetam safe in polytherapy?
   Yes, due to low drug interaction potential.
6. What type of seizures does it treat?
   Both focal and generalized seizures.

References

• Goodman & Gilman’s The Pharmacological Basis of Therapeutics – Antiepileptic Drugs
• Katzung: Basic and Clinical Pharmacology – Antiepileptic Drugs
• Tripathi: Essentials of Medical Pharmacology
• Harrison’s Principles of Internal Medicine – Epilepsy Management

Download